Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.
2.

An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia.

Montgomery JH, Byerly M, Carmody T, Li B, Miller DR, Varghese F, Holland R.

Control Clin Trials. 2004 Dec;25(6):598-612. Review.

PMID:
15588746
3.

Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database.

Turner EH, Knoepflmacher D, Shapley L.

PLoS Med. 2012;9(3):e1001189. doi: 10.1371/journal.pmed.1001189. Epub 2012 Mar 20.

4.

How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.

Suzuki T, Uchida H, Watanabe K, Nomura K, Takeuchi H, Tomita M, Tsunoda K, Nio S, Den R, Manki H, Tanabe A, Yagi G, Kashima H.

Psychopharmacology (Berl). 2007 Dec;195(2):285-95. Epub 2007 Aug 14.

PMID:
17701027
5.

Quetiapine for schizophrenia.

Srisurapanont M, Maneeton B, Maneeton N.

Cochrane Database Syst Rev. 2004;(2):CD000967. Review.

PMID:
15106155
6.

Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.

Mladsi DM, Grogg AL, Irish WD, Lopez RB, Degen K, Swann A, Nimsch CT.

Curr Med Res Opin. 2004 Dec;20(12):1883-93.

PMID:
15701206
7.

New generation antipsychotics for first episode schizophrenia.

Rummel C, Hamann J, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2003;(4):CD004410. Review.

PMID:
14584012
8.

Effectiveness of switching antipsychotic medications.

Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA.

Am J Psychiatry. 2006 Dec;163(12):2090-5.

PMID:
17151159
9.

Typical and atypical antipsychotics in bipolar depression.

Gao K, Gajwani P, Elhaj O, Calabrese JR.

J Clin Psychiatry. 2005 Nov;66(11):1376-85. Review.

PMID:
16420074
10.

Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.

Dossenbach M, Arango-Dávila C, Silva Ibarra H, Landa E, Aguilar J, Caro O, Leadbetter J, Assunção S.

J Clin Psychiatry. 2005 Aug;66(8):1021-30.

PMID:
16086618
11.

Cost of antipsychotic polypharmacy in the treatment of schizophrenia.

Zhu B, Ascher-Svanum H, Faries DE, Correll CU, Kane JM.

BMC Psychiatry. 2008 Apr 4;8:19. doi: 10.1186/1471-244X-8-19.

12.

A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders.

Jensen JB, Kumra S, Leitten W, Oberstar J, Anjum A, White T, Wozniak J, Lee SS, Schulz SC.

J Child Adolesc Psychopharmacol. 2008 Aug;18(4):317-26. doi: 10.1089/cap.2007.0123.

PMID:
18759641
13.

A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.

Sacchetti E, Valsecchi P, Parrinello G; QUERISOLA Group.

Schizophr Res. 2008 Jan;98(1-3):55-65. Epub 2007 Oct 15.

PMID:
17933497
14.

Atypical antipsychotics for disruptive behaviour disorders in children and youths.

Loy JH, Merry SN, Hetrick SE, Stasiak K.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD008559. doi: 10.1002/14651858.CD008559.pub2. Review.

PMID:
22972123
15.

Aripiprazole versus other atypical antipsychotics for schizophrenia.

Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh HG, Leucht S, Xia J.

Cochrane Database Syst Rev. 2014 Jan 2;(1):CD006569. doi: 10.1002/14651858.CD006569.pub5. Review.

PMID:
24385408
16.

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia.

Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM.

Am J Psychiatry. 2009 Feb;166(2):152-63. doi: 10.1176/appi.ajp.2008.08030368. Epub 2008 Nov 17.

PMID:
19015230
17.
18.

Antipsychotics for delirium.

Lonergan E, Britton AM, Luxenberg J, Wyller T.

Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005594. Review.

PMID:
17443602
19.

Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.

Kruse G, Wong BJ, Duh MS, Lefebvre P, Lafeuille MH, Fastenau JM.

Pharmacoeconomics. 2015 Oct;33(10):1049-67. doi: 10.1007/s40273-015-0285-8. Review.

PMID:
25963579
20.

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.

Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK; CATIE Investigators.

Am J Psychiatry. 2007 Mar;164(3):415-27.

PMID:
17329466

Supplemental Content

Support Center